Evolocumab in STEMI

Sponsor
Sejong General Hospital
Study ID
NCT06081803
Phase
PHASE3
Status
Active Not Recruiting

Conditions

  • ST Elevation Myocardial Infarction

Eligibility Criteria

Sex
ALL
Age
30 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Repatha® — DRUG
    Repatha® 140mg x 3 pens subcutaneous injection

Study Details

The goal of this clinical trial is to compare the size of myocardial infarct between evolocumab and control groups in patients with ST segment elevation myocardial infarction who undergoing primary percutaneous coronary intervention(PCI). All study participants will undergo a cardiac MRI 4 weeks after primary reperfusion. The evolocumab group will receive 420 mg before PCI via subcutaneous injection.

Key Dates

Start date
Dec 5, 2020
Status verified
Jun 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
166 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Evolocumab group
    Evolocumab 420mg subcutaneous injection before primary PCI
  • No Intervention: Control group
    without Evolocumab 420mg before primary PCI

Primary Outcome Measure

Myocardial infarct size [ Time Frame: 1 month after primary reperfusion ]

Related coverage on Hipa.ai

Related Studies